Drug General Information
Drug ID	D0L7WS
Former ID	DIB015270
Drug Name	RX-3117
Synonyms	Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
Indication	Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10:C00-C75, C7A, C7B, D10-D36, D3A]		Phase 1	[524590]
Company	Rexahn
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	DNMT1	Target Info	Inhibitor	[532483]
KEGG Pathway	Cysteine and methionine metabolism
	Metabolic pathways
	MicroRNAs in cancer
Pathway Interaction Database	Regulation of retinoblastoma protein
PathWhiz Pathway	Methionine Metabolism
Reactome	PRC2 methylates histones and DNA
	NoRC negatively regulates rRNA expression
	DNA methylation
WikiPathways	Trans-sulfuration and one carbon metabolism
	Retinoblastoma (RB) in Cancer
	One Carbon Metabolism
	Trans-sulfuration pathway
References
Ref 524590	ClinicalTrials.gov (NCT02030067) Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies. U.S. National Institutes of Health.
Ref 532483	Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.